Colchicine at Its Ceiling, or a Biologic Instead
A young woman with genetically confirmed FMF keeps having attacks despite colchicine dose increases — the real question underneath the biologic decision is whether her disease is resistant, or whether GI side effects have kept her from ever actually reaching an adequate dose.
Nadia S., a 24-year-old graduate student of Armenian descent, was diagnosed with familial Mediterranean fever at nineteen after a genetics workup confirmed a homozygous MEFV mutation, following a decade of recurrent episodes her family had always called “the stomach thing.” Colchicine controlled her attacks well for the first two years — fewer than one a year, none severe enough to miss classes. Over the past year that has changed: three breakthrough attacks, each with the same pattern of fever, one-sided abdominal pain severe enough to bring her to urgent care twice, and a day or two of large-joint arthralgia that resolves on its own.
Her colchicine dose has been raised twice, most recently to 1.8 mg/day, and each increase has been followed within a week by worsening diarrhea significant enough that she has, by her own admission, sometimes skipped a dose the next morning rather than risk being unable to leave her apartment before an exam. That detail changes what her breakthrough attacks are actually evidence of. True colchicine resistance — the category the CLUSTER trial (De Benedetti et al.) enrolled before demonstrating canakinumab's benefit in FMF, hyperimmunoglobulin D syndrome, and TRAPS together — assumes a genuine, sustained trial at an adequate dose, and Nadia's actual exposure has been intermittent by her own report, not because the mutation has stopped answering to the drug, but because the drug's own GI burden has repeatedly cut her effective dose below what was prescribed. She otherwise has no other chronic medical conditions, takes no other regular medications, and had, until this past year, described her FMF as something she rarely thought about between the occasional flare — a baseline that makes the past year's shift feel to her like a real and unexplained deterioration rather than the expected course of a stable disease. Her renal function remains normal and her most recent urine protein/creatinine ratio unremarkable — reassuring for now, though each additional year of poorly controlled inflammation carries real, cumulative AA amyloidosis risk regardless of which explanation, intolerance or true resistance, turns out to be correct. That risk is the actual reason today's visit carries more urgency than her own description of “just some bad diarrhea” might otherwise suggest.
Clinic visit, third breakthrough attack this year
Before we call this colchicine-resistant, I want a genuine trial at an adequate, actually-taken dose — which by her own account, she hasn't had. The GI side effects are real, not an excuse, but they have a real fix: splitting the daily dose into two or three smaller doses substantially improves tolerability without lowering the total, and that alone resolves a meaningful share of what looks like resistance in practice.
If we escalate to a biologic on the strength of an inadequately-tolerated trial, we may be committing her to lifelong injectable therapy for a problem dose-splitting could have solved.
I hear the distinction, but from where I sit the practical outcome is the same either way: three breakthrough attacks in a year, on a drug she is not able to sustain at the dose that would actually control her disease, with amyloidosis risk accumulating in the meantime. The CLUSTER trial's own eligibility criteria captured intolerance alongside true resistance for exactly this reason — the label doesn't require sorting out which one it is before treating.
You're right dose-splitting might work — but 'might' is doing a lot of work in a plan that asks her to tolerate another cycle of breakthrough attacks while we find out, when canakinumab has direct trial evidence in patients who look exactly like her.
I've seen her through every one of these attacks over five years, and I don't think we need to guess which one this is — her pharmacy refill history is right here, and it shows exactly the pattern she's describing: full fills at the higher dose, followed by a gap, followed by a partial refill, three times over the year. That's intolerance-driven underdosing, not resistance.
Given that, I'd try dose-splitting with scheduled loperamide support for two months before concluding the drug has failed her — a real, time-limited trial, not an open-ended one. If attacks continue on a dose she is actually and verifiably taking, the case for canakinumab becomes the strongest kind: confirmed resistance, not unconfirmed intolerance, which is exactly the population the trial evidence speaks to most directly.
Agreed: colchicine dose-split to three times daily at the same 1.8 mg total, scheduled loperamide during the trial, and pharmacy refill records reviewed monthly rather than relying on self-report alone — the primary care physician's direct evidence resolved what had looked like a genuine three-way disagreement into a single, bounded plan.
If attacks recur despite documented full-dose adherence over the two-month window, canakinumab starts without further debate — the rheumatologist and clinical pharmacologist agreed in advance on that trigger, so the decision doesn't have to be relitigated attack by attack.